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Detection of Angiotensin II in Supernatants of Stimulated
Mononuclear Leukocytes by Matrix-Assisted Laser Desorption
Ionization Time-of-Flight/Time-of-Flight Mass Analysis
Vera Jankowski, Raymond Vanholder, Markus van der Giet, Lars Henning, Markus To¨lle,
Gilbert Scho¨nfelder, Anja Krakow, Sevil Karadogan, Niklas Gustavsson, Johan Gobom, Jessie Webb,
Hans Lehrach, Gu¨nther Giebing, Hartmut Schlu¨ter, Karl F. Hilgers, Walter Zidek, Joachim Jankowski
Abstract—Angiotensin II (Ang II) is the major vasoactive component of the renin-angiotensin system. Several components
of the renin-angiotensin system have been demonstrated in different tissues. Whereas the roles of tissue and renal
renin-angiotensin system have been studied in detail, much less is known on whether the corpuscular elements of
circulating blood contribute to Ang II production. Here we examined whether, in addition to vasculature, blood cells also
contribute to the circulating Ang II levels. Mononuclear leukocytes were obtained from healthy subjects and were
incubated. The resulting supernatant was chromatographed using different chromatographic methods. The vasocon-
strictive effects of aliquots of the resulting fractions were tested. Each fraction with a vasoconstrictive effect was
analyzed by mass spectrometry. In one fraction with a strong vasoconstrictive effect, Ang II was identified.
Mononuclear lymphocytes produced Ang II in amounts sufficient to stimulate Ang II type 1 receptors. Moreover, in
mononuclear leukocytes, renin as well as angiotensin-converting enzyme mRNA expression was detectable by RT-PCR.
These findings demonstrate that mononuclear leukocytes are a source of Ang II. Ang II secretion by these cells may play
a significant role in humoral vascular regulation. In conclusion, the isolation of Ang II in supernatants of mononuclear
leukocytes adds a further physiological source of Ang II to the current view of angiotensin metabolism. The quantitative
role of lymphocyte-derived Ang II secretion compared with the other sources of Ang II should be defined further, but
the release found under the present conditions is at least sufficient to elicit vasoconstrictive effects. (Hypertension.
2005;46:591-597.)
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Whereas angiotensin II (Ang II) was first regardedmerely as a potent vasoconstrictor, at present, its
functions as a growth factor and as a cytokine are more and
more recognized. The renin-angiotensin system (RAS) is
known to mediate systemic Ang II production,1,2 but Ang
II is also produced locally in many tissues.3–5 This local
Ang II production, depending on tissue RAS, has recently
attracted growing interest.6 – 8
In the classical RAS, circulating renal-derived renin
produces Ang I by cleaving angiotensinogen. In the lungs,
Ang I is converted to Ang II by the angiotensin-converting
enzyme (ACE).9 –11 ACE is found in plasma as well as in
most organs. Tissue ACE may play a role in the regulation
of tissue perfusion.12 Angiotensinogen and ACE, but not
renin, have been found to be produced in all layers of the
vessel wall.13–15
Therefore, local generation of Ang II is probably depen-
dent on circulating renin. Of potential relevance to the
pathophysiological role of RAS is the recent observation
indicating that adipose tissue is a significant source of
circulating angiotensinogen and hence possibly contributes to
the regulation of blood pressure and sodium homeostasis.16
Whereas the roles of tissue and renal RAS have been
studied in detail, much less is known on whether the corpus-
cular elements of circulating blood contribute to Ang II
production. Therefore, we also examined whether cellular
components of the circulating blood contribute to the circu-
lating Ang II levels. The experiments showed that, indeed, a
fraction of circulating mononuclear leukocytes is a source of
Ang II in humans, especially if they are activated. These
findings are more relevant because leukocyte activation and
adhesion have been linked to vascular damage.17
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Details of the chemicals used in this study are available in the online
supplement at http://www.hypertensionaha.org.
Mononuclear Leukocyte Isolation
Preparation of Mononuclear Leukocytes
The description of the mononuclear leukocytes preparation is avail-
able in the online supplement.
Incubation of Mononuclear Leukocytes
Mononuclear leukocytes were incubated without or with 10 mg L1
lipopolysaccharide (LPS; LPS serotype 0111:B4 from Escherichia
coli; Sigma-Aldrich) or 200 nmol/LG-1 formyl-Met-Leu-
phenylalanine (fMLP).18 After incubation for 60 minutes, mononu-
clear leukocytes were centrifuged and the supernatant analyzed.
Isolation of CD8 (T Lymphocytes) and
CD19 (B Lymphocytes)
The description of the isolation of CD8 and CD19 is available in
the online supplement.
Analytical Techniques
The description of the chromatographic and mass-spectrometric
procedures is available in the online supplement.
Measurement of Perfusion Pressure in Isolated
Perfused Rat Kidney
The effects of aliquots (1/10) of the lyophilized fractions of the
reversed-phase chromatography on vascular tone, aliquots (1/10) of
supernatant of mononuclear leukocytes, and synthetic Ang II were
evaluated in an isolated rat kidney perfused with a constant flow
while perfusion pressure was monitored continuously. Details of the
preparation are given previously19 as well as in the online
supplement.
Vasoconstrictor responses of the isolated perfused rat kidney were
assessed at basal tone after an equilibration period of 30 minutes.
Samples were dissolved in 200 L of the perfusion solution
described above. To characterize the receptor mediating the vaso-
constrictive effect of the fraction, aliquots of fractions were also
tested after the Ang II receptor antagonist saralasin (50 mol/L1)
was added to the perfusate, 30 minutes before challenge with the
fractions to be tested.
Molecular Methodology
Preparation of RNA and RT-PCR
The preparation of RNA and the RT-PCR conditions are available in
the online supplement.
Detection of Renin and ACE Activity of Mononuclear
Leukocytes by MALDI Mass Spectrometry
To detect the renin and ACE activity of mononuclear leukocytes, a
previously described method was used.20 The description of the
method is available in the online supplement. Briefly, the proteins
potentially present in the lysate of mononuclear leukocytes were
immobilized to bromine-cyan (CNBr)–activated Sepharose 6 mac-
robeads (MB; Amersham-Pharmacia Biotech). Next, 25-L beads
containing the immobilized proteins were transferred into a 500-L
reaction vial. A total of 10 L of a suspension containing 5104
mol/L1 renin-substrate (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-
Leu-Leu-Val-Tyr-Ser), 8105 mol/L1 Ang I, or 2106 mol/L1
angiotensinogen (from human plasma) was added. Moreover, to
detect whether angiotensinogen was present in the cytosol of
mononuclear leukocytes, 25-L beads containing the immobilized
proteins were incubated with the lysates of mononuclear leukocytes,
prepared as described in the online supplement.
Each incubation experiment was performed in the absence and in
the presence of an ACE inhibitor (Bachem; Ang I–converting
enzyme [Cyanoac-Phe-Phe-OH]; 103 mol/L1) and a renin inhibitor
(D-His-Pro-Phe-His-Leu-Psi-[CH2NH]-Leu-Val-Tyr), which was
used at a concentration achieving maximum renin inhibition. This
inhibitor was used at a concentration achieving maximum renin
inhibition (105 mol/L1).21 From the reaction mixture, 0.5-L
aliquots were removed after 5 minutes, 2 hours, 4 hours, 12 hours,
and 48 hours for analysis of the reaction products. The products of
the enzymatic activity were analyzed by MALDI mass analysis using
the conditions described above.
Verification of renin, ACE, angiotensinogen, Ang I, and Ang II
content of the isotonic NaCl solution was used as washing step for
isolation of mononuclear leukocytes.
To verify the efficiency of the washing procedure of the mono-
nuclear leukocytes in removing plasma renin, ACE, and angiotensin,
the proteins potentially present in the isotonic NaCl solution of the
third washing step were also immobilized to activated CNBr–
Sepharose 6 MB beads (Amersham-Pharmacia Biotech) using the
method described in the online supplement. Next, these CNBr–
Sepharose 6 MB beads were incubated with renin substrate (Asp-
Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser) or Ang I in
the absence or presence of ACE inhibitor and a renin inhibitor
(D-His-Pro-Phe-His-Leu-Psi-[CH2NH]-Leu-Val-Tyr) as described
above. Moreover, the amount of Ang I and Ang II in the kept isotonic
NaCl solution of the third washing step was quantified by chromato-
graphic assays as described above.
Verification of Ang II Determination by MALDI Mass
Spectrometry With Ang II Radioimmunoassay
Details of the verification of Ang II determination by MALDI mass
spectrometry (MS) with the Ang II radioimmunoassay (RIA) are
available in the online supplement.
Statistics
All data are presented as meanSEM. Where error bars do not
appear in the figure, errors are within the symbol size. Statistical
analyses were performed with the Wilcoxon-Mann–Whitney test or
with the Kruskal–Wallis test for multiple comparisons.
Results
After isolation of human mononuclear leukocytes from human
blood by centrifugation, the cell viability was 98.10.4%
(n4). After incubation at 25°C for 60 minutes with or without
stimuli, the supernatant was concentrated and fractionated by
cation-exchange chromatography. A characteristic chromato-
gram is illustrated in Figure 1A. The fractions of each gradient
step of the cation-exchange chromatography were then further
chromatographed by reversed-phase chromatography. The
reversed-phase chromatography, on the one hand, allows us to
desalt the eluate of the cation exchanger and, on the other hand,
to further fractionate the eluate.
The fractions obtained from each reversed-phase chroma-
tography were tested for vasoactivity. In Figure 1A, the
fraction yielding vasoactive on further fractionation is labeled
by the arrow. The reversed-phase chromatography obtained
with this fraction is shown in Figure 1B. The vasoconstrictive
fraction as detected is indicated by the arrow.
The vasoconstrictive substance contained in the vasoactive
fraction labeled in Figure 1B was identified by MS. In this
fraction, a peptide with a molecular weight of m/z of 1046.5
was detected (Figure 2A). This peptide was fragmented to
obtain sequence information that could be used for identifi-
cation by searching in the Swissprot database (Figure 2B).
Human Ang II was the highest-ranking match for the peptide
at m/z 1046.5, with complete amino acid sequence coverage.
This result was confirmed by comparison to a fragment ion
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spectrum of purified human Ang II (Bachem). The mass
signal of Ang I was not detected in Figure 2A because Ang
I was not eluted in the same cation-exchange fraction as
Ang II.
Figure 3A shows that, indeed, Ang II and the vasoactive
fraction obtained from lymphocytes show very similar pro-
files of vascular effects. In 5 experiments, the effect of the
vasoconstrictive fraction amounted to 74.18.4 mm Hg (Fig-
ure 3B). In the presence of saralasin, the vasoconstrictive
effect decreased by 59.81.4%. A comparison to the
concentration-response curve of Ang II (Figure 3C) shows
that if the observed hemodynamic changes are attributable of
Ang II, indeed, significant amounts of Ang II can be assumed
to be present in this fraction.
From these findings, the question arose of which fraction of
the mononuclear cells would be responsible for the production of
Ang II. Therefore, the different fractions of mononuclear leuko-
cytes were separated and were tested for expression of angio-
tensinogen, renin, and ACE. As shown in Figure 4, CD8
(Figure 4A) and CD19 (Figure 4B) expressed angioten-
sinogen–cDNA but also renin–cDNA and ACE–cDNA, thus
being capable of producing Ang II without the need of being
supplied with any of its precursors. Furthermore, in CD8 and
CD19 lymphocytes, Ang II production was monitored sepa-
rately. In both lymphocyte subsets, Ang II production was
detectable by MS (Figure 4C and 4D). The identity of Ang II
was confirmed by MS/MS time-of-flight/time-of-flight (TOF-
TOF) analysis.
To also confirm the detection of lymphocytic angioten-
sinogen, renin, and ACE expression on a functional level,
mass spectrometric Ang I and Ang II measurements were
done under conditions chosen to prove the existence of these
proteins. Immobilized lymphocytic proteins were incubated
with lymphocytic cell lysate for 8 hours. Under these condi-
tions, Ang II production was observed but was completely
abolished by adding the renin inhibitor (data not shown). Ang
I and Ang II production was also demonstrable when, instead
of lymphocytic cell lysate, the synthetic renin substrate
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser
was added (Figure 5A). Ang II production was abolished in
the presence of a renin inhibitor (Figure 5A). Moreover, Ang
II production was detectable after incubation with Ang I
(Figure 5B). From these findings, the presence of renin in
mononuclear leukocytes and the presence of the substrate of
renin, angiotensinogen, can be concluded. After adding an
ACE inhibitor (Figure 5B), Ang II production was blocked
completely, additionally indicating the presence of ACE in
the immobilized lymphocyte extract. Moreover, to exclude
that Ang I might have been produced from the renin substrate
by some other enzyme than renin, because the synthetic renin
substrate may be cleaved unspecifically by several pepti-
dases, purified angiotensinogen was added instead of the
renin substrate. The experiments revealed that also after
addition of angiotensinogen, Ang I and Ang II were produced
(Figure 5C). Again, the Ang II production was abolished by
renin inhibitor (Figure 5C). After addition of renin substrate,
Figure 1. A, Cation-exchange chromatography of the superna-
tant of mononuclear leukocytes after 60-minute incubation. The
vasoactive fraction is indicated by the arrow, the dotted line
showing the extent of the fraction. B, Reversed-phase chroma-
tography of the eluate of the cation-exchange chromatography.
The fraction with a vasoconstrictive effect is indicated by the
arrow, the dotted line showing the extent of the fraction.
Figure 2. A, Identification of the substance with the vasocon-
strictive effect labeled in Figure 1B by the arrow. MALDI-TOF
mass spectra obtained from the vasoconstrictive fraction of the
reversed-phase high-performance liquid chromatography sepa-
ration. B, Fragment ion mass spectrum of the peptide at m/z
1046.5. In the top part of the panel, the amino acid sequences
for the matched a, b, and y-ion series are indicated.
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Ang II concentrations in the supernatants exceeded those of
Ang I, whereas after addition of angiotensinogen, Ang I was
generated in higher concentrations than Ang II. These differ-
ent patterns may be explained, assuming that renin has a
higher affinity to angiotensinogen than to the renin substrate,
so that Ang I is generated faster from angiotensinogen than
from renin substrate. To ensure that mass spectrometry–
derived data on Ang II concentrations are valid, we deter-
mined Ang II concentrations in supernatants from mononu-
clear leukocytes by mass spectrometry and a conventional
RIA-based assay. Figure 5D shows that the mass-
spectrometric method used in this study is in good accordance
with the RIA-based method described by Hilgers et al.22
Next, we had to exclude that the detected renin and ACE
activity was caused by contaminations from plasma renin and
ACE. Therefore, the proteins of the isotonic NaCl solution of
the third washing step of the isolation of mononuclear
leukocytes were immobilized and incubated with renin sub-
strate and Ang I. After an incubation time of 8 hours with
renin substrate, no Ang II production was detected by the
MALDI mass spectrometry assay (data not shown).
Next, the question arose whether mononuclear leukocytes
do not only produce Ang II but also secrete Ang II into the
circulation. The amount of Ang II in the supernatant was
quantified (relative to internal standard). After a 120-minute
incubation of mononuclear cells without stimulation, Ang II
concentration in the supernatant was 0.170.05 (relative Ang
II intensity [arbitrary units]). The addition of fMLP and LPS
leads to a significant increase of Ang II concentration in the
supernatant (fMLP versus LPS 0.370.06 versus 0.360.07
[relative Ang II intensity; arbitrary units]). From the quanti-
tative relationship between MS signals and underlying Ang II
concentrations, we estimated that after stimulation 9.96.6
fmol Ang II (106 lymphocytes)1 min1 was secreted. The cell
suspension used contained 5.080.98 103 mononuclear lym-
phocytes L1, which is in the same order of magnitude as
the mononuclear leukocyte count in human blood. For un-
stimulated cells, the same algorithm leads to an Ang II
production rate of 4.71.7 fmol Ang II (106 lymphocytes)1
min1. Therefore, unstimulated lymphocytes should also con-
tribute amounts of Ang II in the same order of magnitude as
stimulated cells. To obtain a valid comparison between
lymphocytic Ang II secretion rates and human Ang II plasma
levels, the latter were also determined by mass spectrometry.
In 6 healthy subjects, plasma Ang II concentrations of
1.800.80 1010 mol/L1 were found.
Discussion
The present findings demonstrate that human circulating
mononuclear leukocytes are a source of Ang II, and that this
secretion is sufficient to stimulate AT receptors. The mech-
anism whereby LPS stimulates Ang II release has been
studied in different tissues.23,24 These studies documented
that LPS stimulates angiotensinogen mRNA expression and
enhances angiotensinogen plasma concentrations. According
to the present estimates, the amount of lymphocytes con-
tained in 1 mL blood can produce 50 fmol Ang II per
minute after stimulation and 20 fmol Ang II per minute
without stimulation, thus increasing the concentration by 50
pmol/L1 per minute after stimulation or 20 pmol/L1 per
minute without stimulation. In consideration of this secretion
rate and given an EC50 in the nanomolar range,25,26 lympho-
cytic Ang II production during 30 minutes would be
sufficient to reach EC50.
Obviously, from the rate of synthesis estimated in this study a
steady-state plasma concentration, which is the net effect of
synthesis and degradation, cannot be calculated without reliable
data on degradation kinetics. Moreover, the degree of stimula-
tion may be different between in vivo and in vitro conditions.
Therefore, the conclusions that can be drawn from lymphocytic
Ang II synthesis in vitro should be restricted to the point that the
order of magnitude of lymphocytic Ang II production is suffi-
cient to contribute to plasma Ang II.
Moreover, we demonstrated by a functional mass spectro-
metric assay that angiotensinogen, renin, and ACE are not
only expressed in human lymphocytes but are also function-
ally relevant for lymphocytic Ang II production. Because
after blocking each of these components, lymphocytic Ang II
Figure 3. Effect of the supernatant of mononuclear leukocytes
stimulated by 10 mg L1 LPS on the perfusion pressure of the
isolated perfused rat kidney. A, Original curve of the increase of
the perfusion pressure of the isolated perfused rat kidney
caused by synthetic Ang II (106 mol/L1) and an aliquot (100
L) of the supernatant of mononuclear leukocytes. B, Quantifi-
cation of the effect of an aliquot (100 L) of the supernatant of
mononuclear leukocytes on the perfusion pressure (n5). C,
Dose-response curve of synthetic Ang II on the perfusion pres-
sure of the isolated perfused rat kidney.
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production was totally neutralized, other pathways of Ang II
synthesis are not necessarily involved in these mononuclear
leukocytes. From the present findings, it appears unlikely that
mononuclear leukocytes merely take up Ang II by receptor
internalization. The latter mechanism would lead to a contin-
uous decrease of extracellular Ang II concentration, whereas
in our experiments, extracellular Ang II increased continu-
ously. We demonstrate that mononuclear lymphocytes pro-
duce and secrete Ang II, but we do not clarify whether these
cells may also store Ang II.
There are several reports pointing out the possibility that in
experimental animals and humans, Ang II might be produced
by immune cells because the expression of several compo-
nents of the RAS, such as ACE27 and angiotensinogen,28 has
been demonstrated.
Several tissues have been shown to produce Ang II, including
endothelial cells,29 macrophages,30 and adipocytes.31 Moreover,
angiotensin peptides are released by rat alveolar macrophages.32
Local Ang II secretion was recognized as an important part of
humoral vascular regulation. There have also been reports
localizing Ang II in the cytoplasm of several types of leukocytes
by immunocytochemistry, but secretion of Ang II by these cells,
making them contributors to circulating Ang II levels, has not
yet been demonstrated.33 Furthermore, it has been shown that
after adding angiotensinogen or Ang I to immune cells, Ang II
production is increased,34 indicating that all enzymes required
Figure 4. Representative gel electro-
phoresis of 4 experiments of products
from RT-PCR using primer against ACE,
renin, angiotensinogen, and -actin
cDNA. Lane 1, 100-bp marker; lane 2,
renin; lane 3, ACE; lane 4, angiotensino-
gen; lane 5, -actin from CD8 cells (A)
and CD19 cells (B) . TOF-TOF mass
spectra of the supernatants of CD8
cells (C) and CD19 cells (D). The
molecular mass labeled in the spectra is
conform to that of Ang II. The identity of
Ang II was confirmed by MS/MS TOF-
TOF analysis.
Figure 5. Detection of renin and ACE activity in a protein extract of mononuclear leukocytes by MALDI-MS. A, Incubation time–dependent
generation by the protein extract of mononuclear leukocytes in the presence of renin substrate of the reaction products Ang I (ƒ) in the
absence of a renin inhibitor, and of Ang II, either in the absence () or in the presence (E) of a renin inhibitor. B, Incubation time–dependent
generation of the reaction product Ang II after the incubation of the protein extract of mononuclear leukocytes with Ang I in the absence ()
and in the presence (E) of an ACE inhibitor. C, Incubation time–dependent generation of the reaction products Ang I (ƒ) in the absence of a
renin inhibitor and Ang II after the incubation of the protein extract of mononuclear leukocytes in the absence () and in the presence (E) of a
renin inhibitor with purified angiotensinogen. Abscissa indicates incubation time; ordinate, ratios of the relative MALDI spectra signal intensi-
ties of the reaction product Ang II (n5; *significance [calculated by Mann–Whitney test]) of relative peptide intensity in the absence or pres-
ence of the inhibitor used; P0.05). D, Quantification of different Ang II concentrations by RIA vs MALDI mass spectrometry.
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for Ang II production are present in these cells. However, it was
not clear whether Ang II production in these cells was mainly
mediated by renin and ACE, like in the classical pathway, or by
other, renin- or ACE-independent enzymes.
What may be the specific role of lymphocyte-derived Ang
II? We speculate that lymphocyte-derived Ang II has not only
a direct vasoconstrictive effect but might also play a role in
modulating immunologic processes in several ways. Using
Agtr1a(/) mice, which lack Ang II type 1A (AT1A)
receptors for Ang II, it was shown that Ang II triggers the
proliferation of splenic lymphocytes.35 These actions of the
RAS to promote lymphocyte activation may contribute to
inflammatory processes. Moreover, experimental mesangial
proliferative glomerulonephritis developing in FcR-deficient
mice surviving from lethal initial damage was prevented by
an AT1 blocker.36 Glomerular injury in FcR-deficient mice is
associated with AT1 receptor–dependent CD4 T-cell infil-
tration mediated by Ang II–activated renal mesangial cells
showing chemotactic activity for T cells.37 Furthermore, a
role of the RAS has been demonstrated in interleukin-12
(IL-12) secretion by macrophages,38 in hematopoietic pro-
cesses in multiple cellular lineages including hematopoietic
progenitor cells,39,40 and in the regulation of transforming
growth factor-b1 secretion by CD4 cells.41 Ang II is active
as a cytokine stimulating IL secretion. Therefore, the Ang II
production by lymphocytes may be regarded as part of an
autocrine loop regulating lymphocytic immune response.
A yet unsolved issue regards the appropriate stimulus of
lymphocytic Ang II secretion. Whereas in juxtaglomerular
cells, the stimuli of renin secretion, which is the rate-limiting
step of Ang II production from circulating angiotensinogen,
are well known, the regulation of lymphocytic Ang II
production has not been examined yet. Unlike juxtaglomer-
ular cells, lymphocytes are not known to be sensors of whole
body sodium chloride balance, thus being devoid of the
afference felt to be most important in renin secretion. Par-
tially analogous mechanisms may underlie renin secretion in
lymphocytes and juxtaglomerular cells.42
In summary, circulating human CD8 and CD19 lym-
phocytes were shown to produce and to secrete Ang II. The
findings thus add a further physiological source of Ang II to
the current view of angiotensin metabolism. The physiolog-
ical role of lymphocyte-derived Ang II secretion remains
open. Nevertheless, the amounts of Ang II secreted by
lymphocytes appear to be sufficient to stimulate AT receptors
and to affect vascular tone.
References
1. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of
action. Physiol Rev. 1977;57:313–370.
2. Reid IA, Morris BJ, Ganong WF. The renin-angiotensin system. Annu
Rev Physiol. 1978;40:377–410.
3. Mu¨ller DN, Bohlender J, Hilgers KF, Dragun D, Costerousse O, Menard
J, Luft FC. Vascular angiotensin-converting enzyme expression regulates
local angiotensin II. Hypertension. 1997;29:98–104.
4. Dell’Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman
GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angio-
tensin II generation in the dog heart. Evidence for independent mech-
anisms in intravascular and interstitial spaces. J Clin Invest. 1997;
100:253–258.
5. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest.
1987;79:1–6.
6. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the
adipose tissue renin-angiotensin system. Hypertension. 2000;35:
1270–1277.
7. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of
intrarenal angiotensin II in hypertension. Hypertension. 2002;39:
316–322.
8. Dostal DE. The cardiac renin-angiotensin system: novel signaling mech-
anisms related to cardiac growth and function. Regul Pept. 2000;91:1–11.
9. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT. Purification and
properties of angiotensin-converting enzyme from hog lung. Circ Res.
1972;31:356–366.
10. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and
molecular biology of the tissue renin angiotensin systems. Regul Pept.
1993;43:1–20.
11. Inagami T. A memorial to Robert Tiegerstedt: the centennial of renin
discovery. Hypertension. 1998;32:953–957.
12. Saris JJ, van Dijk MA, Kroon I, Schalekamp MA, Danser AH. Functional
importance of angiotensin-converting enzyme-dependent in situ angio-
tensin II generation in the human forearm. Hypertension. 2000;35:
764–768.
13. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel
wall: evidence, possibilities and hypotheses. J Hypertens. 1989;7:
933–936.
14. Naftilan AJ. Role of the tissue renin-angiotensin system in vascular
remodeling and smooth muscle cell growth. Curr Opin Nephrol
Hypertens. 1994;3:218–227.
15. Morgan L, Pipkin FB, Kalsheker N. Angiotensinogen: molecular biology,
biochemistry and physiology. Int J Biochem Cell Biol. 1996;28:
1211–1222.
16. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regu-
lation of the human adipose-tissue renin-angiotensin system: relationship
to obesity and hypertension. J Hypertens. 2002;20:965–973.
17. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;
340:115–126.
18. Orie NN, Zidek W, Tepel M. Tyrosine and calcium/calmodulin kinases
are common signaling components in the generation of reactive oxygen
species in human lymphocytes. Life Sci. 1999;65:2135–2142.
19. van der Giet M, Khattab M, Borgel J, Schlu¨ter H, Zidek W. Differential
effects of diadenosine phosphates on purinoceptors in the rat isolated
perfused kidney. Br J Pharmacol. 1997;120:1453–1460.
20. Jankowski J, Stephan N, Knobloch M, Fischer S, Schmaltz D, Zidek W,
Schlu¨ter H. Mass-spectrometry-linked screening of protein fractions for
enzymatic activities-a tool for functional genomics. Anal Biochem. 2001;
290:324–329.
21. Wood JM, Gulati N, Forgiarini P, Fuhrer W, Hofbauer KG. Effects of a
specific and long-acting renin inhibitor in the marmoset. Hypertension.
1985;7:797–803.
22. Hilgers KF, Bingener E, Stumpf C, Muller DN, Schmieder RE, Veelken
R. Angiotensinases restrict locally generated angiotensin II to the blood
vessel wall. Hypertension. 1998;31:368–372.
23. Klett C, Hellmann W, Ganten D, Hackenthal E. Tissue distribution of
angiotensinogen mRNA during experimental inflammation. Inflam-
mation. 1993;17:183–197.
24. Nyui N, Tamura K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M,
Kihara M, Ochiai H, Miyazaki N, Umemura S, Ishii M. Tissue angioten-
sinogen gene expression induced by lipopolysaccharide in hypertensive
rats. Hypertension. 1997;30:859–867.
25. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, Vauquelin G. An-
giotensin IV is a potent agonist for constitutive active human AT1
receptors. Distinct roles of the N-and C-terminal residues of angiotensin
II during AT1 receptor activation. J Biol Chem. 2002;277:23107–23110.
26. Fierens FL, Vanderheyden PM, Roggeman C, Vande Gucht P, De Backer
JP, Vauquelin G. Distinct binding properties of the AT(1) receptor an-
tagonist 3H-andesartan to intact cells and membrane preparations.
Biochem Pharmacol. 2002;63:1273–1279.
27. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin
I-converting enzyme in human circulating mononuclear cells: genetic
polymorphism of expression in T-lymphocytes. Biochem J. 1993;290:
33–40.
28. Gomez RA, Norling LL, Wilfong N, Isakson P, Lynch KR, Hock R,
Quesenberry P. Leukocytes synthesize angiotensinogen. Hypertension.
1993;21:470–475.
596 Hypertension September 2005
29. Leung PS, Chan HC, Wong PY. Immunohistochemical localization of
angiotensin II in the mouse pancreas. Histochem J. 1998;30:21–25.
30. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence
that macrophages in atherosclerotic lesions contain angiotensin II. Cir-
culation. 1998;98:800–807.
31. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the
adipose tissue renin-angiotensin system in the pathophysiology of obesity
and obesity-related disorders. Obes Rev. 2003;4:43–55.
32. Dezso B, Jacobsen J, Poulsen K. Evidence for the presence of angioten-
sins in normal, unstimulated alveolar macrophages and monocytes.
J Hypertens. 1989;7:5–11.
33. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD.
Evidence that angiotensin II is present in human monocytes. Circulation.
1995;91:1129–1134.
34. Weinstock JV, Blum AM. Granuloma macrophages in murine schistoso-
miasis mansoni generate components of the angiotensin system. Cell
Immunol. 1984;89:39–45.
35. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amucha-
stegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates
cellular immune responses through a calcineurin-dependent pathway.
J Clin Invest. 1999;104:1693–1701.
36. Suzuki Y, Shirato I, Okumura K, Ravetch JV, Takai T, Tomino Y, Ra C.
Distinct contribution of Fc receptors and angiotensin II-dependent
pathways in anti-GBM glomerulonephritis. Kidney Int. 1998;54:
1166–1174.
37. Suzuki Y, Gomez-Guerrero C, Shirato I, Lopez-Franco O, Hernandez-
Vargas P, Sanjuan G, Ruiz-Ortega M, Sugaya T, Okumura K, Tomino Y,
Ra C, Egido J. Susceptibility to T cell-mediated injury in immune
complex disease is linked to local activation of renin-angiotensin system:
the role of NF-AT pathway. J Immunol. 2002;169:4136–4146.
38. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril
suppress production of interleukin-12 by human peripheral blood mono-
nuclear cells. Immunol Lett. 1998;62:25–31.
39. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angio-
tensin(1-7) on hematopoietic recovery after intravenous chemotherapy.
Cancer Chemother Pharmacol. 2003;51:97–106.
40. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on
hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287–294.
41. Chen K, Wei Y, Sharp GC, Braley-Mullen H. Inhibition of TGFbeta1 by
anti-TGFbeta1 antibody or lisinopril reduces thyroid fibrosis in granulo-
matous experimental autoimmune thyroiditis. J Immunol. 2002;169:
6530–6538.
42. Della Bruna R, Kurtz A, Corvol P, Pinet F. Renin mRNA quantification
using polymerase chain reaction in cultured juxtaglomerular cells.
Short-term effects of cAMP on renin mRNA and secretion. Circ Res.
1993;73:639–648.
Jankowski et al Identification of Angiotensin II in Leukocytes 597
